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Abstract—Patients with Acute Kidney Injury (AKI) increase 
mortality, morbidity, and long-term adverse events. Therefore, 
early identification of AKI may improve renal function 
recovery, decrease comorbidities, and further improve patients' 
survival. To control certain risk factors and develop targeted 
prevention strategies are important to reduce the risk of AKI. 
Drug-drug interactions and drug-disease interactions are 
critical issues for AKI. Typical statistical approaches cannot 
handle the complexity of drug-drug and drug-disease 
interactions. In this paper, we propose a novel learning 
algorithm, Deep Rule Forests (DRF), which discovers rules from 
multilayer tree models as the combinations of drug usages and 
disease indications to help identify such interactions. We found 
that several disease and drug usages are considered having 
significant impact on the occurrence of AKI. Our experimental 
results also show that the DRF model performs comparatively 
better than typical tree-based and other state-of-the-art 
algorithms in terms of prediction accuracy and model 
interpretability. 
Keywords—acute kidney injury, drug-drug interactions, 
interpretable machine learning, rule learning, representation 
learning 
I. INTRODUCTION 
Acute kidney injury (AKI) is a severe adverse event 
characterized by rapid decline of renal function, as a leading 
cause of complications, disability, and mortality [1]. Acute 
care, intensive care unit, or general ward often encounter 
patients with AKI, caused by underlying medical conditions 
or inappropriate drug usage. Despite there being standard care 
for patients with AKI, the mortality rate remains high. The 
mortality rate in severe AKI is about 50% to 60% [2]. 
Therefore, early diagnosis and treatment of AKI could help 
renal recovery, avoid complications, and improve patients’ 
survival rate. 
Nephrotoxic drugs are involved in 19-25% of the cases 
with severe AKI in critically ill patients [3], [4]. However, 
AKI caused by drug-drug interactions (DDI) or drug-disease 
interactions (DDX) is preventable, as many such interactions 
can be identified, and drugs can be substituted with less-
nephrotoxic ones. The reversibility of AKI is related to the 
duration of risk factors exposure and the severity of the injury 
[5]. Therefore, predicting and avoiding unexpected AKI is 
substantial for clinical practice. DDI may occur in 
simultaneous drug exposure, which causes decreasing or 
increasing the action of multiple drugs [6]. For example, the 
drug combinations of angiotensin-converting enzyme 
inhibitor (ACEI)/Angiotensin II Receptor Blocker (ARB), 
diuretic, and nonsteroidal anti-inflammatory drug (NSAID) 
could precipitate AKI. This concurrent drug use is also known 
as “triple whammy” to the kidney [7]. As a consequence, 
healthcare providers should inform patients with kidney 
dysfunction to avoid NSAID exposure. 
It is difficult for typical statistical methods, such as logistic 
regression models, to identify complex DDIs and DDXs. 
Patients with higher disease severity usually have more 
comorbidities and drug prescriptions, so many interactions 
between diseases and drugs could be found. We propose a 
novel approach, Deep Rule Forests, based on random forest 
[8] and a deep architecture-like ensemble learning algorithm 
to identify significant DDIs and DDXs. Our proposed 
approach with layer-wise rule forests can discover latent 
interactions/rules that potentially trigger AKI.  
The rest of this paper is organized as follows. In Section 
II, we discuss and review background related to DDI and 
DDX identifications along with machine learning algorithms 
in literature. We elaborate our proposed approach in Section 
III. In Section IV, we present our findings with the evaluations 
of model performance and interpretability. We conclude and 
summarize in Section V. 
II. BACKGROUND AND RELATEDD WORK 
There are more than 5,000 and 295 cases per million 
people per year requiring non-dialysis care and dialysis 
treatment in the U.S., respectively [9]. Prescribed drugs, such 
as radiocontrast agents, NSAIDs, antibiotics (β-lactam 
inhibitors, aminoglycosides, sulphonamides), antifungal 
agents (amphotericin), anti-viral agents (acyclovir), 
antihypertensive drugs (ACEI, ARB) are found contributing 
to AKI [10]. However, how to detect the AKI risk among the 
combinations of these drugs is still little known.  
Inappropriate drug prescription is one of the most common 
causes of AKI. For example, the prescription of diuretics, 
ACEIs/ARBs, or NSAIDs in volume-depleted patients can 
exacerbate the AKI event [11]. These drugs can decrease renal 
perfusion and the amount of glomerular filtration rate. 
Besides, antibiotics, such as beta-lactam inhibitors, 
aminoglycosides, and sulfonamides, may cause acute 
interstitial nephritis. Furthermore, AKI caused by post-renal 
obstruction could be found in acyclovir (anti-viral agent) or 
Sulfonamide (antibiotics) in patients with inadequate fluid 
status [12]. 
Beyond the well-known nephrotoxic agents, several 
common prescription drugs were also found potentially 
nephrotoxic. For example, Dormuth et al. used a logistic 
regression model to estimate the increased risk of AKI in high 
potency statins (lipid-lowering drug) [13]. Besides, Shih et al. 
found the increased risk of AKI among dipeptidyl peptidase-
4 inhibitor (glucose-lowering drug) users compared to 
nonusers in a conditional logistic regression model with 
confounders adjustment [14]. Furthermore, McCoy et al. 
employed univariate comparisons between the pre-
intervention and post-intervention periods with the Pearson 
Chi-square test for categorical variables and the log-rank test 
for the time from events to predict response variables. These 
studies are precise to measure the modification or 
discontinuation rate per 100 events for medications included 
in the interruptive alert within 24 hours of increasing 
creatinine improved [15]. However, these studies did not 
provide specific information on co-occurrence drug exposure 
and the risk of AKI. 
Drug-drug interactions (DDIs) occur when two or more 
drugs react with each other, which may cause increasing or 
decreasing drug reaction, unexpected side effects, and even 
death of the patients [16]. DDIs are the crucial issues in 
clinical practice, accounting for 2-6% of all hospital 
admissions, and estimating about 500 million pounds annual 
cost by UK National Health Service [17]. The use of 
interacting medications has increased since 2005, accounting 
for 15% of senior Americans at the risk increment of DDIs 
[18]. The more drugs the patients take, the more likely they 
would interact [19]. Juurlink et al. investigated the association 
between medication use and hospital admission due to drug 
toxicity. Most hospitalization of elderly patients occurs after 
the administration of a drug triggering drug-drug interaction. 
They concluded that many of these drug interactions could be 
avoided [20]. Yue et al. used the best-first strategy to search 
the space of feature subsets, and iteratively expand the subset 
according to the rule of best Merit value and continue to use 
lasso regression to select highly correlated features/variables. 
However, their results show that it can only increase the 
accuracy of the model prediction. We still do not know which 
combinations of drug usages might cause DDIs [21].  
Besides, Adverse Drug Reaction (ADR) often results 
either from the prescription of a single drug or a particular 
class of DDIs [22]. Among them, taking nephrotoxic drugs is 
one of the high-risk factors for AKI. Nephrotoxic drugs 
involved in 19-25% of the cases with severe AKI in critically 
ill patients [3], [4]. Among patients with kidney diseases, 
polypharmacy is common to cause DDIs, which may cause 
unexpected adverse effects and even death [21]. Some ADRs 
are predictable and preventable, including known DDIs and 
DDXs [23]. For example, drug interaction between calcium 
channel blocker (blood pressure-lowering drug) and 
Clarithromycin (antibiotics) was found to increase the risk of 
AKI [24]. However, it is time-consuming to evaluate the DDIs 
and DDXs one by one because of the complexity of multiple 
comorbidities and polypharmacy in patients. Still, it is 
challenging for typical statistical approaches, such as 
generalized linear models) to take into account multiple 
interaction terms within one model. That is, pre-defining 
suitable interaction terms does help such statistical approaches 
get better prediction, but it is almost impossible and time-
consuming for researchers to manually identify them. 
Nevertheless, rule learning methods, such as RIPPER 
[25], rule-based C5.0 [26] and CART [27], may help 
automatically identify aforementioned interactions in patient 
prescription and healthcare history data. Such machine 
learning algorithms have been widely used in different fields, 
especially when interpretability is a concern. In rule-based 
learning algorithms, conjunctive clauses (AND-rules) and 
disjunctive clauses (OR-rules) are often one-level rules [28]. 
Among these rule learners, rules from tree-based methods are 
different from typical rule-based learning algorithms [28]. 
Tree-based methods mainly divide data into smaller subsets 
by choosing a series of split points known as rules. These rules 
are in conjunctive normal form (CNF; AND-of-ORs) and split 
data space into mutually exclusive regions as shown in Fig. 1. 
In Fig. 1, we can observe that the tree separates iris data [30] 
into three regions by choosing two split points. In other words, 
complicated interaction of feature status can be represented as 
regions, which provide more representational power than 
original features. This technique is established in the field of 
representation learning [31], the set of methods that identifies 
appropriate representations of data so that learning tasks can 
perform better in terms of accuracy than using the original 
data. Namely, the goal of representation learning is to 
automatically identify data transformations that map raw input 
features into representations that are more suitable for specific 
machine learning tasks. Therefore, in such cases, manual and 
cumbersome features extractions are not required [31]. In 
recent decades, ensemble learning with tree-based algorithms, 
such as random forest [8] and XGBoost [32], were proposed. 
These learning algorithms combine multiple trees into a forest 
with row resampling and column sampling techniques, and 
therefore they usually have more expressive power to discover 
signals/patterns in data. They are efficient rule learners, but 
their rules may conflict or overlap and thus the rules are hard 
to be directly interpreted by humans. 
 
Fig. 1. The tree structure and the scatter plot of the decision tree applied to 
iris data [30] 
Aside from obtaining diverse/distributed representations 
to increase expressive power, combining and reusing the 
existing representations is another way to boost the expressive 
power of a model. One popular example is the rise of deep 
neural networks and deep model architecture [33], [34], in 
which the network weights are used to perform linear and non-
linear transformations and combinations in layer-wise 
fashions. Bengio et al. [35] argue that representation learning 
has two advantages: the first is that deep architecture promotes 
the reuse of features. The concept of reuse explains the power 
of distributed representation and is the core theory behind 
deep learning [34]. The second is that deep architecture leads 
to features that become progressively more abstract in higher-
level representations. Observed empirically, layer-wise 
stacking of feature extractions sometimes produces better 
representations [31], [36]. On the other hand, researchers have 
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proposed tree-based models with deep architectures, too. For 
example, Forward Thinking: Building Deep Random Forest 
(FTDRF) [37] and Deep Forest [38], have been proposed to 
stack multiple random forests into multilayer structures. In 
both algorithms, random forest in every layer will generate the 
predicted probability matrix as the new input data for the 
following layer. The probability matrices can be considered as 
a series of compressions of input features in the layer-wise 
fashion. These compressed representations can be further 
applied to other supervised machine learning methods, e.g. 
linear model, tree-based model, or multilayer perceptron 
(MLP) [34]. The aforementioned tree-based representation 
learning methods may potentially increase the accuracy of 
model prediction. However, they are still black-box models. 
The representations in the form of a probability matrix are 
incomprehensible, as they are simply the predicted 
probabilities of the target classes. Therefore, in order to 
provide interpretable and more expressive data 
representations, we propose our representation learning 
method that discovers DDIs and DDXs in disjunctive normal 
form (DNF; OR-of-ANDs) of rules. These discovered sets of 
rules are able to represent complex DDIs and DDXs. The 
importance of found DDIs and DDXs can also be further 
determined by other learning algorithms, such as linear 
models and tree-based models. 
III. DETECTION OF DDIS/DDXS FOR AKI—USING DEEP 
RULE FOREST 
We propose a novel learning algorithm, Deep Rule Forest 
(DRF), that helps discover and extract rules from the 
combinations of disease conditions and drug usages. DRF 
maps data into rule representations using modified random 
forests in a layer-wise fashion. In Fig. 2, the table on the left 
represents the raw data, with each row indicating a doctor 
visiting record and each column indicating a patient feature 
(such as information on the patient’s medical history and 
medications). After obtaining decision trees by applying 
random forest algorithm to the raw data, in the arrows (i), we 
map the observations of the training set into the containing 
regions with rules extracted from random forest. The arrow 
(ii) shows that the collated table of containing regions on the 
right side is prepared for generating another random forest in 
the next layer. 
The granularity of rules in regions is determined by the 
number of tree splits. When a tree grows more deeply, it can 
handle more complex datasets but will also generate more 
complicated rules. The depth of decision trees controls how 
much information would be transmitted during rule mapping, 
which is also considered the model capacity. A fine-grained 
decision tree can map a dataset into relatively more regions, 
which raise the model capacity of information transmitting. 
However, if a decision tree grows too deep, it often tends to 
overfit the training data [39]. Therefore, the granularity of 
decision trees is a critical and considered a hyper-parameter of 
our proposed DRF. Fine-tuning hyper-parameters of the DRF 
can be considered as lowering validation errors step by step in 
deep neural networks [40]. Therefore, it depends on the 
difficulty of learning tasks. 
We propose to construct the DRF model with multiple 
layers based on the notion of deep architecture [35]. The DRF 
automatically discovers rules from the variable-level features 
to the region-wise representations. Furthermore, hierarchical 
representation learning is constituted by the formation of 
higher-layer features through the compositions of low-layer 
features. Fig. 3 illustrates how to learn layer-wise distributed 
region representations of data. In the beginning of the training 
process, each tree in the 1st layer generates mutually exclusive 
regions/rules formed in CNF. Followed by the 1st layer, each 
tree in the successive layers performs splitting by choosing the 
appropriate set of regions in the selected trees in the previous 
layer. The procedure of finding appropriate sets of regions can 
reconstruct multiple CNF rules with OR-operators and reform 
the rules into DNF. In Fig. 3, take the first split of T2.1 as an 
example, DRF samples a set of trees from the 1st layer. Tree 
T1.1 and some branches/regions are selected as they can 
further minimize the Gini index impurity. This selection 
process can automatically be done by stacking the random 
forest models with region/rule-encoded representations of the 
data. The rules are gradually combined and refined in the 
successive layers. Such multilayer learning architecture 
naturally provides the sharing and reuse of components [36]. 
These hierarchical combining representations based on 
multilayer decision trees are of more expressive power with 
nested CNF and DNF [29].  
Fig. 2. Training flow of DRF with the AKI dataset 
As mentioned previously, representations in DRF are in 
the form of DNF rules eventually. These representations can 
be used with other machine learning methods, such as decision 
tree, linear model, and Bayesian network. In Section IV, we 
demonstrate and explain how to fit a lasso regression model 
with these region representations and calculate odds ratios for 
various DDIs and DDXs represented as logic expressions. In 
short, DRF compresses original input features and then 
transforms them into region-wise representations layer by 
layer. This procedure would generate several region tables 
corresponding to individual layers. Hence, these region tables 
can be used in further tasks such as fitting a classification 
model or prediction. 
 
Fig. 3. Learning region-wise representations layer by layer 
IV. EXPERIMENTAL RESULTS 
A. Data Source 
The data used in this study is Longitudinal Health 
Insurance Databases 2000, randomly sampled one million 
beneficiaries from original Taiwan’s National Health 
Insurance Research Database (NHIRD) [38]. Subjects with 
age more than 18 years were enrolled. We excluded 
participants with regular dialysis (hemodialysis or peritoneal 
dialysis) before January 1, 2000, and those who died before 
April 1, 2000. We investigate subjects with at least one disease 
related to AKI, including diabetes mellitus, hypertension, 
hyperlipidemia, chronic kidney disease, heart failure, atrial 
fibrillation, peripheral artery disease, coronary artery disease, 
cerebrovascular disease (ischemic stroke or hemorrhagic 
stroke), chronic lung disease (chronic obstructive pulmonary 
disease or asthma), gout, autoimmune disease, malignancy, 
dementia, and psoriasis. We included 40 drug groups 
including histamine-2 blockers, proton pump inhibitors, anti-
arrhythmic drugs, antidepressants, antiepileptics, antiplatelets, 
warfarin, antipsychotic agents, benzodiazepines, medications 
for chronic obstructive pulmonary disease treatment, digoxin, 
loop diuretics, thiazide, potassium-sparing diuretics 
(spironolactone), blood glucose-lowering drugs (insulin, 
acarbose, metformin, sulfonylurea, thiazolidinedione), blood 
pressure-lowering drugs (ACEI, ARB, beta-blocker, calcium 
channel blocker), hypnotics, immunosuppressive agents, 
lipid-lowering drugs (fibrate, statin), osteoporosis drugs, anti-
parkinsonism drugs, uric lowering drugs, antibiotics (Beta-
lactam, Macrolide, Quinolone, Tetracycline), antifungal 
drugs, anti-viral drugs, NSAID (traditional NSAID, 
cyclooxygenase-2 inhibitors), other pain killers (opioid), and 
steroid. The identified comorbidities and drug prescriptions 
were recorded in each clinic visit. Participants were followed 
up until their deaths, the occurrence of AKI events, or until 
December 31, 2008, whichever comes first. There are 61,663 
patients/observations. 
B. Performance Evaluation 
Again, the DRF model is a kind of representation learning 
method derived from tree-based methods and is constructed in 
a layer-wise fashion. Here, we compare the rule 
representations learned from DRF with raw features using 
single decision tree methods and elastic net [41]. We also 
consider other state-of-the-art learning algorithms with raw 
data, including random forest [8], XGBoost [32], and MLP 
[34]. 
The complexity of rules is determined by the number of 
tree nodes. We empirically set up a total of three layers in 
DRF, whose first and second layers were purposed to obtain 
more information, and the last was used to filter out excessive 
information which might include noise in the data. There were 
100 trees in each layer. In the first two layers, the diversity of 
trees in one layer was formatted in the mixed numbers of leaf 
nodes, which were between 2 to 11. In the last layer, the 
diversity of trees was limited to grow into 3 leaf nodes per tree. 
We used the R programming language [42] along with its 
packages to conduct experiments. R Package rpart, C50, 
RWeka built-in JRip, xgboost, ranger, keras, and H2O are 
used to learn CART, C4.5 (and rule-based C5.0), RIPPER, 
XGBoost, random forest, MLP, and elastic net models, 
respectively. The number of trees in the random forest, 
XGBoost, and each layer of the DRF was empirically set to 
100. MLP was formed by two hidden layers with 16 and 8 
neurons. In the experiments, due to the target variable is with 
imbalanced classes, we chose the area under the ROC curve 
(AUC) as the performance evaluation measure. Table I shows 
the testing AUC comparison among different learning 
algorithms.  
The result shows that the proposed DRF with different 
classifiers perform better compared to other black-box models 
trained with raw data. Both CART and elastic nets trained with 
DRF’s representations perform comparatively better than 
these two algorithms trained with the raw data. In most cases, 
models with DRF’s data representations have more expressive 
power than those with raw data. It also suggests that learning 
DRF with multi-level rule representations with more layers 
may be able to identify more patterns (i.e. DDIs and DDXs) 
and thus result in higher accuracy of predictions. 
C. Rule Learning for Model Interpretability 
Table II shows that the rules (drug-drug and drug-disease 
interactions) learned from rule-based learning algorithms, 
including CART, C4.5, rule-based C5.0, and RIPPER. 
According to the experiment in Section IV, the elastic net 
trained with DRF in the 2nd layer has the highest AUC. 
Therefore, we compare the top five crucial rules from this 
model in Table III. On the other hand, DRF is trained layer by 
layer, and thus the rules can express the medical history and 
medications into DNF, as shown in Table III. Rules in DNF 
are able to represent more complicated representations 
(DDIs/DDXs). 
TABLE I.  AUC COMPARISON AMONG DIFFERENT COMBINATIONS OF 
DATA REPRESENTATIONS AND ALGORITHMS 
Data  
Algorithm 
CART [43] C4.5 [26] C5.0 [26] 
RIPPER 
[44] 
Raw data 0.723 0.760 0.760 0.682 
 
Elastic net 
[41], [45] 
Random 
forest [46] 
XGBoost 
[32] 
MLP [47] 
Raw data 0.755 0.769 0.762 0.782 
 
DRF + CART 
[43] 
DRF + C4.5 [26] 
DRF + Elastic 
net [41], [45] 
DRF in  
1st layer 
0.726 0.750 0.779 
2nd layer 0.718 0.734 0.782 
3rd layer 0.760 0.757 0.766 
TABLE II.  RULES COMPARISON OF RULE-BASED MODELS 
Algorithm Rule 
# of records 
(Positive) 
CART 
CCB (Calcium channel blockers) & 
DIU (Loop diuretics) 
6,010(177) 
C4.5 
Age = 60-79 & H2B (H2 blockers) & 
HTN (Hypertension) & Economic level 
in (2nd, 3rd) & COP (COPD medications)  
34(9) 
Rule-based 
C5.0 
MET & Age = 18-39 6,433(33) 
RIPPER DM (Diabetes mellitus) 120(117) 
TABLE III.  RULES COMPARISON OF ELASTIC NET TRAINED FROM DRF 
IN THE 2ND LAYER 
Importance Rule 
# of records 
(Positive) 
1st important 
(L2.T3=r1) 
MET | NSA | (NSA & P_CKD) | BZD 
| (BZD & PSD) | ACE |  
(ACE & DIU) 
27,307(377) 
2nd important 
(L2.T2=r2) 
(SUL & P_CKD & STA) | SUL | 
(SUL & P_CVAD) | PAI | STA | 
|(STA & P_CVAD) | (SUL & 
P_CKD) 
87,154 
(1,891) 
3rd important 
(L2.T2=r1) 
P_CKD 572(13) 
4th important 
(L2.T1=r2) 
PAI & P_CKD 
41,835 
(1,444) 
5th important 
(L2.T1=r1) 
ACE | MET | PAI 45,891(460) 
D. AKI Risk in DDI or DDX 
The experimental result also suggests that each rule can 
cover a sub-group of patient records, and subjects with these 
rules are at high risk of AKI. Fig. 4 shows that the top five 
groups/rules/regions that denote those who may have a high 
risk of AKI. The numbers below black points are estimates of 
odds ratios of a logit model. Fig. 4 suggests that, for example, 
those who have taken MET (Metformin), NSA (NSAIDs), 
NSA with CKD (chronic kidney disease), BZD 
(Benzodiazepines), a combination of BZD and PSD 
(Spironolactone), ACE (ACEI), or combination of ACE 
(ACEI) and DIU (loop diuretics) are 3.19 times more likely to 
have AKI than the others. According to the rules from the raw 
data, we demonstrate traditional NSAIDs as one of the top 
important factors related to AKI. Reported from systematic 
review and meta-analysis can confirm our finding of AKI 
risks in traditional NSAID users [48]. Besides, metformin 
(MET), which is the most common oral antidiabetic agents for 
type 2 diabetes treatment, is also associated with AKI episode. 
Metformin associated lactic acidosis is usually reported in 
patients with AKI [49]. However, the metformin and AKI 
association should be interpreted as a consequence, rather than 
causality. The concurrent use of ACEI and loop diuretics may 
potentially increase the risk of AKI, especially in hypovolemic 
status or additional NSAID exposure [50]. Our finding of 
increased AKI risk in concomitant use of benzodiazepines and 
spironolactone is novel. The AKI episode after 
benzodiazepines used was demonstrated in the case report 
[51]. Further study to evaluate the risk of AKI in co-current 
use of benzodiazepines and spironolactone is needed. 
 
Fig. 4. Odds ratio with 95% confidence intervals generated from the elastic 
net model, which was trained with the 2nd  layer of DRF 
V. CONCLUSION 
In this paper, we propose a novel rule-based feature 
learning technique, Deep Rule Forests, that helps discover 
DDIs and DDXs that may potentially induce AKI. We found 
that our proposed approach performs comparatively better 
than typical rule-based algorithms and the update-to-date 
black-box algorithms in terms of model interpretability and 
accuracy of prediction, respectively. This work could help 
researchers and physicians to identify adverse drug reactions 
when drugs are used alone or in combinations. Also, we can 
obtain multiple sets of DDIs and DDXs that may cause AKI 
as well as exhaustive rules if there are multiple layers in the 
DRF model. 
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